​

Galectin Therapeutics (GALT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

GALT Stock Rating

Galectin Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (72.73%), 3 Hold (27.27%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 3 8 Strong Sell Sell Hold Buy Strong Buy

GALT Price Target Upside V Benchmarks

TypeNameUpside
StockGalectin Therapeutics-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.34$1.34$1.34
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25--1--1
May, 25--1--1
Apr, 25--1--1
Mar, 25--1--1
Feb, 25--1--1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.74-----
Avg Forecast$-0.48$-0.73$-0.92$-1.14$-0.67$-1.08
High Forecast$-0.48$-0.73$-0.92$-1.14$-0.67$-1.08
Low Forecast$-0.48$-0.73$-0.92$-1.14$-0.67$-1.08
Surprise %54.17%-----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast$64.73M$208.00M$36.32M$179.69M$385.24M$572.22M
High Forecast$64.73M$208.00M$36.32M$179.69M$385.24M$572.22M
Low Forecast$64.73M$208.00M$36.32M$179.69M$385.24M$572.22M
Surprise %------

Net Income Forecast

$-70M $-61M $-52M $-43M $-34M $-25M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-41.07M-----
Avg Forecast$-28.88M$-43.92M$-55.35M$-68.58M$-40.31M$-64.97M
High Forecast$-28.88M$-43.92M$-55.35M$-68.58M$-40.31M$-64.97M
Low Forecast$-28.88M$-43.92M$-55.35M$-68.58M$-40.31M$-64.97M
Surprise %42.21%-----

GALT Forecast FAQ

Is Galectin Therapeutics stock a buy?

Galectin Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Galectin Therapeutics is a favorable investment for most analysts.

What is Galectin Therapeutics's price target?

Galectin Therapeutics's price target, set by 11 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.34.

How does Galectin Therapeutics stock forecast compare to its benchmarks?

Galectin Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Galectin Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Galectin Therapeutics’s EPS forecast?

Galectin Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.73, marking a -1.35% decrease from the reported $-0.74 in 2023. Estimates for the following years are $-0.92 in 2025, $-1.14 in 2026, $-0.67 in 2027, and $-1.08 in 2028.

What is Galectin Therapeutics’s revenue forecast?

Galectin Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $208M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $36.32M, followed by $179.69M for 2026, $385.24M for 2027, and $572.22M for 2028.

What is Galectin Therapeutics’s net income forecast?

Galectin Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-43.916M, representing an 6.94% increase from the reported $-41.066M in 2023. Projections indicate $-55.346M in 2025, $-68.581M in 2026, $-40.307M in 2027, and $-64.972M in 2028.